肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展*

doi:10.3969/j.issn.1672-5069.2024.06.039

Abstract

Abstract: The mechanisms of hepatocarcinogenesis have not been fully elucidated. Krüppel-like factors (KLFs), the largest family of zinc finger protein (ZFP) transcription factors in humans, have recently been found to play a promoting or inhibiting role in hepatocellular carcinoma (HCC) progression. Basic and clinical studies have shown that part of KLFs might be used as molecular markers for diagnosis and for predicting prognosis of patients with HCC. It is also possible as a molecular targets for gene therapy. This article reviews the tissue distribution, expressing features and clinical application of HCC-related KLFs.

Key words: Hepatocellular carcinoma, Krüppel-like factors, Diagnosis, Molecular target

Wang Lingling, Yao Min, Yao Dengfu. Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2024, 27(6): 953-956.

References

[1] McGlynn KA, Petrick JL, El-Serag HB.Epidemiology of hepatocellular carcinoma. Hepatology, 2021, 73(S1):4-13.
[2] Shah PA, Patil R, Harrison SA.NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology, 2023, 77(1):323-338.
[3] Jen J, Wang YC.Zinc finger proteins in cancer progression. J Biomed Sci, 2016, 23(1):53.
[4] Liu Y, Ma D, Ji C.Zinc fingers and homeoboxes family in human diseases. Cancer Gene Ther, 2015, 22(5):223-226.
[5] Caria CA, Faà V, Ristaldi MS. Krüppel-like factor 1: A pivotal gene regulator in erythropoiesis. Cells, 2022, 11(19):3069.
[6] Taghehchian N, Maharati A, Akhlaghipour I, et al.PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression. Cancer Cell Int, 2023, 23(1):233.
[7] Tian B, Zhou L, Wang J,et al. miR-660-5p-loaded M2 macrophages-derived exosomes augment hepatocellular carcinoma development through regulating KLF3. Int Immunopharmacol, 2021, 101(Pt B):108157.
[8] Jia X, Li L, Wang F,et al. DUB3/KLF4 combats tumor growth and chemoresistance in hepatocellular carcinoma. Cell Death Discov, 2022, 8(1):166.
[9] An T, Dong T, Zhou H,et al. The transcription factor Krüppel-like factor 5 promotes cell growth and metastasis via activating PI3K/AKT/Snail signaling in hepatocellular carcinoma. Biochem Biophys Res Commun, 2019, 508(1):159-168.
[10] Vetter D, Cohen-Naftaly M, Villanueva A,et al. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology, 2012, 56(4):1361-1370.
[11] Guo Y, Chai B, Jia J,et al. KLF7/VPS35 axis contributes to hepatocellular carcinoma progression through CCDC85C-activated β-catenin pathway. Cell Biosci, 2021, 11(1):73.
[12] Wang MD, Xing H, Li C,et al. A novel role of Krüppel-like factor 8 as an apoptosis repressor in hepatocellular carcinoma. Cancer Cell Int, 2020, 20:422.
[13] Sun J, Wang B, Liu Y,et al. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Lett, 2014,355(1):25-33.
[14] Li D, Lu L, Liu M,et al. Inhibition of long noncoding RNA cancer susceptibility candidate 7 attenuates hepatocellular carcinoma development by targeting micro RNA-30a-5p. Bioengineered, 2022,13(4):11296-11308.
[15] Hujie G, Zhou SH, Zhang H,et al. MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma. Cancer Cell Int, 2018, 18:10.
[16] Wang J, Pu J, Zhang Y,et al. DANCR contributed to hepatocellular carcinoma malignancy via sponging miR-216a-5p and modulating KLF12. J Cell Physiol, 2019, 234(6):9408-9416.
[17] Chen CC, Xie XM, Zhao XK,et al. Krüppel-like factor 13 promotes HCC progression by transcriptional regulation of HMGCS1-mediated cholesterol synthesis. J Clin Transl Hepatol, 2022, 10(6):1125-1137.
[18] Zhou H, Chen J, Fan M,et al. KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive elementbinding protein 2.J Exp Clin Cancer Res, 2023, 42(1):5.
[19] Jiang Z, Elsarrag SZ, Duan Q,et al. KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. Sci Adv, 2022, 8(10):eabj2917.
[20] Sun N, Shen C, Zhang L,et al. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.Gut, 2021, 70(11): 2183-2195.
[21] Liu FY, Deng YL, Li Y,et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol, 2013, 30(1):425.
[22] Pei J, Grishin NV.C2H2 zinc finger proteins of the SP/KLF, Wilms tumor, EGR, Huckebein, and Klumpfuss families in metazoans and beyond.Gene, 2015, 573(1): 91-99.
[23] Yerra VG, Drosatos K.Specificity proteins (SP) and Krüppel-like factors (KLF) in liver physiology and pathology.Int J Mol Sci, 2023, 24(5):4682.
[24] Fu M, Blackshear PJ.RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins. Nat Rev Immunol, 2017, 17(2):130-143.
[25] Zeng L, Zhu Y, Moreno CS, et al.New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy. Semin Cancer Biol, 2023, 90(1):29-44.
[26] Hu K, Zheng QK, Ma RJ, et al.Kruppel-like factor 6 splice variant 1: An oncogenic transcription factor involved in the progression of multiple malignant tumors. Front Cell Dev Biol, 2021, 9:661731.
[27] Cheng S, Zhang X, Xu Y,et al. Krüppel-like factor 8 regulates VEGFA expression and angiogenesis in hepatocellular carcinoma. Sci Rep, 2018, 8(1):17415.
[28] Li Y, Yu S, Li L, et al.KLF4-mediated upregulation of CD9 and CD81 suppresses hepatocellular carcinoma development via JNK signaling. Cell Death Dis, 2020, 11(4):299.
[29] Kong LM, Yao L, Lu N,et al. Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. Oncotarget, 2016, 7(19):27975-27987.
[30] Memon A, Lee WK. KLF10 as a tumor suppressor gene and its TGF-beta signaling. Cancers (Basel), 2018, 10(6):161.
[31] Ali A, Zhang P, Liangfang Y, et al. KLF17 empowers TGF-beta/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression. Cell Death Dis, 2015, 6(3):e1681.
[32] 赛文莉, 王理, 孙建英, 等. 锌指蛋白转录因子Krüppel样因子5异常表达对肝细胞癌诊断及预后的价值. 中华肝脏病杂志, 2021,29(8):781-787.
[33] Wu W, Liu S, Liang Y, et al.MiR-7 inhibits progression of hepatocarcinoma by targeting KLF-4 and promises a novel diagnostic biomarker. Cancer Cell Int, 2017, 17:31.
[34] Xue M, Zhou C, Zheng Y, et al.The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. Aging (Albany NY), 2020, 12(15):15566-15580.
[35] Zhang Y, Yao C, Ju Z, et al.Krüppel-like factors in tumors: Key regulators and therapeutic avenues. Front Oncol, 2023, 13:1080720.

Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Shaobo, Zhang Shugeng, Liu Lianxin. Immunotherapy in hepatocellular carcinoma patients after liver transplantation:Current knowledge and future perspectives [J]. Journal of Practical Hepatology, 2024, 27(6): 801-803.
[2]	Zheng Hao, Zhang Shugeng, Wang Jiabei, et al. Therapeutic strategies for patients with recurrent hepatocellular carcinoma after liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 804-807.
[3]	Zhu Zebin, Zhang Shugeng, Liu Lianxin. Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 808-811.
[4]	Zhou Jun, Zhang Zhongxin, Xu Haiyan. Assessment of significant liver fibrosis by visual instantaneous elastography and acoustic palpation elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(6): 832-835.
[5]	Wu Yu, Han Yuxing, Xu Manman, et al. Hospital profit and deficit of medical costs in patients with acute-on-chronic liver failure based on DRG payment reform [J]. Journal of Practical Hepatology, 2024, 27(6): 882-886.
[6]	Tang Min, Zeng Li, Yang Xinrong. FibroTouch and virtual touch tissue quantification parameters in evaluating liver fibrosis in patients with schistosomiasis-induced liver disease [J]. Journal of Practical Hepatology, 2024, 27(6): 887-890.
[7]	Chen Siyan, Guo Daoning, Zou Xiaopan, et al. Assessment of stent function by color Doppler ultrasonography in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2024, 27(6): 899-902.
[8]	Zeng Wang, Cai Xiaoman, Ge Shang. Enhanced MRI manifestation feature in differential diagnosis of ICC and HCC: A single center study [J]. Journal of Practical Hepatology, 2024, 27(6): 907-910.
[9]	Danba Yuzhen, Cheng Pan. Gd-EOB-DTPA-enhanced MRI scan in diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 911-914.
[10]	Yang Jiaxin, Yang Zijun, Chen Wei. Image quality and diagnostic efficacy of dual-source CT dual-energy TNC technique in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 915-918.
[11]	Deng Na, Zheng Yufeng, Liu Xuhong, et al. Diagnostic efficacy of CT dynamic enhancement scan in patients with liver cirrhosis and intrahepatic space-occupying lesions [J]. Journal of Practical Hepatology, 2024, 27(6): 919-922.
[12]	Ma Ziyao, Wang Chao, Zhao Jue, et al. MRI and DWI feature in patients with atypical hepatic abscess [J]. Journal of Practical Hepatology, 2024, 27(6): 931-934.
[13]	Li Xiaobin, Liu Bowen, Hu shiping. Lipid metabolic reprogramming in the carcinogenesis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 957-960.
[14]	Wei Xinhuan, Liu Yali, Zhang Jing, et al. Current landscape and future perspectives of metabolic-associated fatty liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 641-645.
[15]	Xie Aiping, Zhao Jing, Jiang Qiming, et al. Prediction of nonalcoholic steatohepatitis by ultrasonic attenuation coefficient or controlled attenuation parameter and liver stiffness measurement combination in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(5): 705-708.